Trypanosomiasis, African Clinical Trial
Official title:
Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.
This trial will study the tolerability and pharmacokinetic of fexinidazole using two different dosage regimen of repeated administrations. The drug is administered to human healthy volunteers of sub-saharan origin together with food, once a day during 10 days, with a loading dose during 4 days.
Objectives:
Primary Objectives: To assess safety and tolerability of two different fexinidazole dosing
regimen, for 10 days repeated administration under fed conditions in healthy male
sub-Saharan volunteers.
Secondary objectives: To validate the exposure to fexinidazole, M1 and M2 after different
dosing regimens in fed conditions for 10 days in order to evaluate the more appropriate
administration regimen for the pivotal phase II/III study.
Methodology/Study Design:
Two dose regimens consisting of repeated oral ascending dose (OAD) dosing in fed condition
with two different ascending loading doses for 4 days followed by the same dose for 6 days
will be evaluated. The study will be conducted in double-blind conditions for both the
clinical and bioanalytical parts.
For each dosing regimen, subjects will reside at the clinical unit from the evening of Day
-2 to the afternoon of Day 17 including an 8 days safety follow up (168 h post last dose).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00489658 -
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
|
Phase 2/Phase 3 | |
Completed |
NCT03087955 -
Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense
|
Phase 2/Phase 3 | |
Completed |
NCT03025789 -
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
|
Phase 3 | |
Completed |
NCT02571062 -
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
|
Phase 1 | |
Terminated |
NCT00330148 -
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
|
Phase 3 | |
Recruiting |
NCT05433350 -
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05645822 -
Screen and Treat Implementation for HAT Control
|
||
Completed |
NCT05947604 -
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
|
Phase 1 | |
Completed |
NCT01533961 -
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
|
Phase 1 | |
Completed |
NCT05256017 -
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT00802594 -
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
|
Phase 2 | |
Completed |
NCT00146627 -
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
|
Phase 3 |